This year’s Canadian Leadership Council on Drug Plan Partnerships presented a unique forum for benefits advisors and pharmaceutical manufacturers. As both sides examined how prescription medications are regulated in Canada and reimbursed by public drug plans, there was a growing awareness that private plan sponsors are conspicuously absent from decision-making processes. The advantages of coordination between public and private plans become increasingly evident as life-changing specialty medications steadily claim a higher share of private-sector spending, while driving down long-term healthcare costs on the public side. Read more about how plan sponsors can take the first steps toward an integrated, health-centred approach for drug coverage in Canada.


  • Amgen
  • GlaxoSmithKline
  • Lilly
  • R&D
  • Sanofi